Navigation Links
Dr. H. Daniel Perez Joins Celtaxsys Board of Directors

SAN FRANCISCO, June 6, 2011 /PRNewswire/ -- Celtaxsys, Inc., a private biopharmaceutical company defining new therapeutics in inflammation, announces the appointment of life sciences industry veteran, H. Daniel Perez, M.D., to its Board of Directors (BOD).

"We are delighted that Dr. Perez has joined the Celtaxsys team," says Dr. Michael R. Hanley, CEO and Chairman of the Board of Celtaxsys. "He brings more than 25 years of high level pharmaceutical executive experience to the BOD, in addition to scientific and commercial accomplishments related to Celtaxsys' mission.  We look forward to working closely with Dr. Perez."  

"I am excited about the opportunities that an innate immunity company brings to the therapeutic field," commented Dr. Perez. "This is an area that is close to my heart and has not received the attention that it deserves.  I believe Celtaxsys will bring new paradigms to the forefront of innovative therapeutics."

H. Daniel Perez, M.D., is a Venture Partner with Bay City Capital, and was previously President and CEO of Berlex Biosciences until its acquisition by Bayer in 2006. He is on the Board of Directors of Cleveland Biolabs (a public company, CBLI), Presidio Pharmaceuticals, and F&P Pharmaceuticals (privately held companies), the Scientific Advisory Boards of Cardium (a public company, CDTP, CXM), Vertex Pharmaceuticals neurodegenerative diseases (VRTX, Nasdaq), Glaxo GSK, (Neuroinflammation, China) and the Advisory Board for the Gladstone Institutes at the University of California, San Francisco (UCSF). Dr. Perez received his medical degree in Buenos Aires, Argentina and completed his medical training at Beth Israel-Mount Sinai and New York University, in New York City. Dr. Perez has published extensively and is the author of a number of patents.

About Celtaxsys

Celtaxsys is a privately-held early discovery company with operations in San Francisco, CA and Atlanta, GA. The Company is focused on the discovery and development of therapeutics to treat inflammation by control of innate immunity. Celtaxsys has pioneered an innovative technology platform to identify novel immunoregulators based on migration and activation of cells from the innate immune system. Lead candidates are undergoing preclinical optimization.

SOURCE Celtaxsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
2. Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services
3. Dr. Daniel Ronel Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
4. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
5. BMP Sunstone Appoints Daniel Harrington to Board of Directors
6. Daniel Dunn Joins Brooks Instrument as Director of Customer Service
7. Rensselaer professor Daniel Lewis receives NSF CAREER Award
8. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
9. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
10. GM Exec Joins Bio-Reaction Industries Board of Directors
11. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... PHILADELPIA, PA (PRWEB) , ... November 24, 2015 , ... ... young entrepreneurs at competitive events in five states to develop and pitch their BIG ... student projects from each state are competing for votes to win the title of ...
(Date:11/24/2015)... Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that ... 2015 at 11:00 a.m. Israel time, at the ... Yigal Allon Street, 36 th Floor, Tel Aviv, Israel ... Paneth and Izhak Tamir to the Board of Directors; ... external directors; , approval of an amendment to certain terms of ...
Breaking Biology Technology:
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
(Date:11/11/2015)... Nov. 11, 2015   MedNet Solutions , an innovative ... clinical research, is pleased to announce that it will be ... (PCT) event, to be held November 17-19 in ... view live demonstrations of iMedNet , MedNet,s ... iMedNet has been able to deliver time and ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
Breaking Biology News(10 mins):